Amgen Aktie News

Delta Air Lines shares could finally take off this year once enough investors can shake off unmerited worries. Drugmaker Amgen's singles and doubles approach to the business makes more sense than always trying for home runs.

A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.

Planning Underway for Phase 3 Development of Tezepelumab in COPD   THOUSAND OAKS, Calif. , April 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic So...

Some of the hottest opportunities can be found in biotech stocks to buy now. With innovation, mergers and acquisitions, major companies looking to replenish their pipelines ahead of patent expirations, treatments for obesity, aging baby boomers, and demand for better care are creating massive opportunities.

Due to its obvious nature, one of the most commonly repeated pieces of advice regarding stock investment is to buy undervalued stocks when they trade low and sell overvalued stocks when they trade high. Achieving this outcome consistently would be ideal.

Amgen has a history of outperforming peers and the market due to its effective capital allocation in the pharmaceutical industry. AMGN is executing well with sales and volume growth, and has a robust development pipeline. Biosimilars growth is accelerating and AMGN currently offers value at the current price along with a respectable and well-covered dividend yield.

Amgen's acquisition of Horizon Therapeutics has made it a major player in the rare disease space, with potential for long-term shareholder return. The company has key pipeline milestones in 2024, focusing on expanding sales of rare disease drugs and advancing drugs in oncology. Despite strong financial results in FY'23, Amgen's valuation is dependent on future growth and managing its significan...

Amgen has been busy with a couple of multi-billion dollar acquisitions over the past few years. While they should create growth opportunities, the drugmaker has also taken on quite a bit of debt.